Nasonex (Mometasone Furoate)

Mometasone furoate is a synthetic glucocorticoid that binds to glucocorticoid receptors in nasal epithelial cells. The drug‑receptor complex alters gene transcription, decreasing the production of inflammatory cytokines, chemokines, and adhesion molecules. This results in reduced vascular permeability, edema, and immune‑cell infiltration, providing anti‑inflammatory effects directly in the nasal mucosa.

The specific dose of Nasonex is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Typical regimens involve one or two sprays per nostril once daily, but exact dosing instructions must be obtained from the prescriber’s order and the product labeling.

Safety data for mometasone furoate in pregnancy are limited, and the product is usually prescribed only if the potential benefit justifies any potential risk to the fetus. Regarding breastfeeding, small amounts may be excreted in milk; therefore, a risk‑benefit assessment should be performed by the clinician before use.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any temperature‑controlled requirements), and import documentation.

Nasonex contains mometasone furoate, a high‑potency glucocorticoid with minimal systemic absorption when used as directed. Compared with older agents such as beclomethasone or fluticasone, mometasone often provides comparable or superior symptom control at similar or lower dosing frequencies, while maintaining a favorable safety profile for long‑term use.

Nasonex should be stored at room temperature, below 25 °C (77 °F). Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use. Do not freeze the product.

Nasonex is administered as a nasal spray. The user should gently blow the nose, insert the nozzle into one nostril, close the opposite nostril with a finger, and press the pump while breathing in gently through the nose. The recommended number of sprays per nostril is specified by the prescriber.

Serious but rare risks include nasal septal perforation, adrenal suppression, elevated intra‑ocular pressure leading to glaucoma or cataract formation, and severe allergic reactions such as anaphylaxis. Patients should report persistent nosebleeds, visual changes, severe headache, or signs of systemic corticosteroid effects to their healthcare provider promptly.

Nasonex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal or sinus infections, and caution is advised for those with uncontrolled glaucoma, cataracts, or systemic fungal infections.